Population Pharmacokinetics of Oral Gecacitinib in Healthy Subjects and Patients with Autoimmune and Inflammatory Diseases
The Journal of Clinical Pharmacology · 2026-06 · 66 (6)
DOI: 10.1002/jcph.70214 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 29.05.2026. Verfasst von Qingheng Meng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Models, Biological, Autoimmune Diseases, Janus Kinase Inhibitors, Sulfonamides. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Gecacitinib is a novel, broad‐spectrum Janus kinase (JAK) inhibitor being developed for the treatment of myelofibrosis, severe alopecia areata, ankylosing spondylitis, and atopic dermatitis. This study aimed to develop population pharmacokinetic (PopPK) models for gecacitinib and its metabolites ZG0244 and ZG0245 to evaluate influential factors. Data from healthy subjects and patients across nine clinical trials were pooled. PopPK models were developed using NONMEM, and covariates of interest were tested. The PopPK structure for gecacitinib was a two‐compartment model with first‐order absorption and linear elimination. The metabolite ZG0244 was best described by a two‐compartment model with Michaelis–Menten formation and linear elimination, while for metabolite ZG0245, it was a one‐compartment model with Michaelis–Menten formation and linear elimination. Statistically significant factors affecting pharmacokinetic parameters included sex, age, indication, and co‐administration with a strong CYP3A inducer or inhibitor. The effects of sex, age, and strong CYP3A inducer on exposure were limited, requiring no dose adjustment. A strong CYP3A inhibitor increased exposure by approximately 1.3‐fold. The median time to reach 95% of steady‐state concentration was approximately 3 days for gecacitinib and ZG0244, and approximately 7 days for ZG0245. This study developed population pharmacokinetic models for gecacitinib and its metabolites, and quantified the effects of covariates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Suzhou Zelgen Biopharmaceuticals Co., Ltd, Suzhou, China.
- Shanghai BioGuider Medical Technology Co., Ltd, Shanghai, China.
ORCID-Profile: Qingheng Meng, Ling Xu
Zitieren
APA
Meng, Q., Zhao, Y., Chen, W., Zhang, L., Xu, L., & Li, L. (2026). Population Pharmacokinetics of Oral Gecacitinib in Healthy Subjects and Patients with Autoimmune and Inflammatory Diseases. The Journal of Clinical Pharmacology, 66(6). https://doi.org/10.1002/jcph.70214
Vancouver
Meng Q, Zhao Y, Chen W, Zhang L, Xu L, Li L. Population Pharmacokinetics of Oral Gecacitinib in Healthy Subjects and Patients with Autoimmune and Inflammatory Diseases. The Journal of Clinical Pharmacology. 2026;66(6). doi:10.1002/jcph.70214
BibTeX
@article{Meng2026,
author = {Meng, Qingheng and Zhao, Yuansheng and Chen, Wenyang and Zhang, Lingxiao and Xu, Ling and Li, Lujin},
title = {Population Pharmacokinetics of Oral Gecacitinib in Healthy Subjects and Patients with Autoimmune and Inflammatory Diseases},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
volume = {66},
number = {6},
doi = {10.1002/jcph.70214}
}
EUVIMED